Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs – Final appraisal document

In DRAFT guidance, NICE recommends guselkumab, alone or with methotrexate, as an option for treating active psoriatic arthritis in adults whose disease has not responded well enough to DMARDs or who cannot tolerate them, and who meet the stated criteria.

Source:

National Institute for Health and Care Excellence